Table I.
Comparison of clinicopathological characteristics between two groups of patients stratified by the CA125 levels.
| Variable | Total, n=306 | CA125 >15 U/ml, n=136 | CA125 ≤15 U/ml, n=170 | P-value |
|---|---|---|---|---|
| Age, years, mean ± SD | 51.9±11.7 | 50.7±12.1 | 52.8±11.4 | 0.116a |
| Sex, male, n (%) | 261 (85.3%) | 114 (83.8%) | 147 (86.5%) | 0.516 |
| Diabetes, n (%) | 68 (22.2%) | 37 (27.2%) | 31 (18.2%) | 0.061 |
| Hypertension, n (%) | 45 (14.7%) | 22 (16.2%) | 23 (13.5%) | 0.516 |
| Platelet count, ×109/l | 178 (135–235) | 199 (149–257) | 171 (129–216) | 0.004b |
| TBIL, µmol/l | 12.7 (9.8–18.0) | 13.7 (10.6–20.9) | 11.8 (9.2–16.0) | 0.001b |
| ALT, IU/l | 54 (30–95) | 56 (33–94) | 45 (27–96) | 0.440b |
| AST, IU/l | 80 (37–130) | 82 (42–132) | 72 (32–125) | 0.503b |
| ALB, g/l, mean ± SD | 37.9±4.47 | 36.8±4.38 | 38.8±4.33 | <0.001a |
| PT, sec, mean ± SD | 14.9±1.67 | 15.0±1.69 | 14.9±1.66 | 0.507a |
| HBV DNA, IU/ml (%) | 0.085 | |||
| ≤2,000 | 193 (63.1%) | 93 (68.4%) | 100 (58.8%) | |
| >2,000 | 113 (36.9%) | 43 (31.6%) | 70 (41.2%) | |
| AFP, ng/ml | 0.015 | |||
| ≤100 | 152 (49.7%) | 57 (41.9%) | 95 (55.9%) | |
| >100 | 154 (50.3%) | 79 (58.1%) | 75 (44.1%) | |
| ASA | 0.286 | |||
| I | 189 (61.8%) | 82 (60.3%) | 107 (62.9%) | |
| II | 105 (34.3%) | 46 (33.8%) | 59 (56.2%) | |
| III | 12 (3.9%) | 8 (5.9%) | 4 (2.4%) | |
| Child-Pugh grade | 0.088 | |||
| A | 243 (79.4%) | 114 (83.8%) | 129 (75.9%) | |
| B | 63 (20.6%) | 22 (16.2%) | 41 (24.1%) | |
| Cirrhosis, n (%) | 259 (84.6%) | 113 (83.1%) | 146 (85.9%) | 0.501 |
| Ascites, n (%) | 80 (26.1%) | 41 (31.1%) | 39 (22.9%) | 0.154 |
| Tumor diameter, cm | 5.5 (3.7–9.0) | 7.0 (4.4–11.1) | 5.0 (3.5–7.5) | <0.001 |
| Tumor number, n (%) | 0.186 | |||
| Solitary | 238 (77.8%) | 101 (74.3%) | 137 (80.6%) | |
| Multiple | 68 (22.2%) | 35 (25.7%) | 33 (19.4%) | |
| TNM stage, n (%) | <0.001 | |||
| I | 152 (49.7%) | 55 (40.4%) | 97 (57.1%) | |
| II | 50 (16.3%) | 18 (13.2%) | 32 (18.8%) | |
| III | 104 (34.0%) | 63 (46.3%) | 41 (24.1%) | |
| Venous invasion (n,%) | 114 (36.3%) | 80 (37.6%) | 34 (33.7%) | 0.503 |
| Tumor differentiation (n,%) | 0.352 | |||
| Well differentiated | 31 (10.1%) | 10 (7.4%) | 21 (12.4%) | |
| Moderately differentiated | 258 (84.3%) | 118 (86.8%) | 140 (82.4%) | |
| Poorly differentiated | 17 (5.6%) | 8 (5.9%) | 9 (5.3%) | |
| Intraoperative blood loss, ml | 500 (200–825) | 500 (200–1,000) | 450 (200–800) | 0.058b |
| Intraoperative transfusion (n,%) | 118 (38.6%) | 65 (47.8%) | 53 (31.2%) | 0.003 |
| Surgery time, min | 180 (144–210) | 180 (150–235) | 180 (140–206) | 0.162b |
| TACE, n (%) | 0.175 | |||
| ≤3 | 268 (87.6%) | 123 (90.4%) | 145 (85.3%) | |
| >3 | 38 (12.4%) | 13 (9.6%) | 25 (14.7%) |
a
Student's t-test
b
Mann-Whitney test. All other data were compared by the χ2 test. CA125, cancer antigen 125; HBV, hepatitis B virus; ASA, American Society of Anesthesiologists; TNM, Tumor-Node-Metastasis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; TBIL, serum total bilirubin; AFP, α-fetoprotein; TACE, transcatheter arterial chemoembolization; ALB, serum albumin.